Advances in Clinical Application of Cerebrospinal Fluid Circulating Tumor DNA in Leptomeningeal Metastasis of Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2024.102.16
- VernacularTitle:脑脊液循环肿瘤DNA在非小细胞肺癌柔脑膜转移中的临床应用进展
- Author:
LI YUBIN
1
;
LI XIAOYAN
Author Information
1. 100070 北京,首都医科大学附属北京天坛医院肿瘤内科
- Keywords:
Lung neoplasms;
Leptomeningeal metastasis;
Cerebrospinal fluid;
Circulating tumor DNA
- From:
Chinese Journal of Lung Cancer
2024;27(5):376-382
- CountryChina
- Language:Chinese
-
Abstract:
Leptomeningeal metastasis(LM)is a lethal complication of malignant tumors,with an incidence rate of 3％-5％among patients with non-small cell lung cancer(NSCLC).LM poses significant challenges in diagnosis,has poor prognosis,limited treatment options,and lacks standardized criteria for evaluating therapeutic efficacy,making it a dif-ficult aspect of NSCLC management.Circulating tumor DNA(ctDNA),shed from tumor cells and carrying cancer-related information,holds significant value in precision oncology.Cerebrospinal fluid(CSF),present in the subarachnoid space of the brain,the spinal cord,and the central canal,and in direct contact with meningeal tissues,serves as the fluid medium that best reflects the genetic characteristics of LM.In recent years,CSF ctDNA has become a focal point due to its multi-omics features,playing a crucial role in the management of central nervous system(CNS)metastatic tumors.Its applications span the entire continuum of care,including aiding in diagnosis,assessing treatment response,predicting prognosis,and analyzing resistance mechanisms.This article provides a concise overview of CSF ctDNA detection techniques and their clinical appli-cations in patients with NSCLC-LM.
